Vimarsana
Biggest News Aggregation in the World

Page 16 - Entrypoint Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Entrypoint Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Entrypoint Capital Today - Breaking & Trending Today

Recent Investment Analysts' Ratings Changes for ServiceNow (NOW) - Vimarsana News

Recent Investment Analysts' Ratings Changes for ServiceNow (NOW)

ServiceNow (NYSE: NOW) has recently received a number of price target changes and ratings updates: 5/10/2024 – ServiceNow had its “outperform” rating reaffirmed by analysts at Wolfe Research. They now have a $830.00 price target on the stock. 5/7/2024 – ServiceNow had its “outperform” rating reaffirmed by analysts at William Blair. 5/7/2024 – ServiceNow had […]

Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) Price Target at $21.33 - Vimarsana News

Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) Price Target at $21.33

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) has earned a consensus recommendation of “Buy” from the six analysts that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last […]

Analysts Set Bloomin' Brands, Inc. (NASDAQ:BLMN) Price Target at $27.50 - Vimarsana News

Analysts Set Bloomin' Brands, Inc. (NASDAQ:BLMN) Price Target at $27.50

Bloomin’ Brands, Inc. (NASDAQ:BLMN – Get Free Report) has been assigned an average recommendation of “Hold” from the ten ratings firms that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among […]

Truist Financial Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $70.00 - Vimarsana News

Truist Financial Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $70.00

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its target price decreased by equities research analysts at Truist Financial from $86.00 to $70.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price target would indicate a potential upside of 45.20% from […]

Source: wkrb13.com
Resources Connection (NASDAQ:RGP) Research Coverage Started at Noble Financial - Vimarsana News

Resources Connection (NASDAQ:RGP) Research Coverage Started at Noble Financial

Noble Financial started coverage on shares of Resources Connection (NASDAQ:RGP – Get Free Report) in a report issued on Wednesday, Benzinga reports. The brokerage set an “outperform” rating and a $15.00 price target on the stock. Noble Financial’s target price would indicate a potential upside of 35.50% from the company’s previous close. A number of […]